A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells

Monica Autiero, Giancarlo Cammarota, Arno Friedlein, Martin Zulauf, Gennaro Chiappetta, Vincenzo Dragone, John Guardiola

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

We previously isolated gp17, a human seminal plasma glycoprotein, which specifically interacts with the D1-D2 region of CD4, a T cell surface molecule involved in antigen recognition mediated by helper T cells also acting as a receptor for the human immunodeficiency virus. In this study we report that monoclonal antibodies (mAb) reacting with gp17 are able to inhibit the binding of gp17 to immobilized soluble CD4. An immunohistochemical analysis shows that gp17 is also expressed in mammary tumor cells upon hormone treatment and in biopsies from breast cancer patients. A structural characterization of gp17, including amino acid sequencing, indicates that the protein has an extensive structural similarity with a glycoprotein designated as seminal actin-binding protein (SABP), also secreted by male sexual glands. SABP is in turn identical to gross cystic disease fluid protein-15 (GCDFP-15) or prolactin-inducible protein (PIP), a factor known as a highly specific and sensitive marker of primary and metastatic apocrine breast cancer. To establish further the correspondence of gp17 and GCDFP-15/PIP/SABP, the latter was expressed in bacteria from a cloned cDNA and purified by affinity chromatography to either anti-gp17 mAb-Sepharose or CD4-Sepharose. The purified recombinant protein is shown to inhibit the binding of labeled, pure g17 to immobilized soluble CD4. The finding that breast cancer cells express a protein able to interact with the CD4 domains involved in the recognition of class II major histocompatibility antigens suggests a possible mechanism by which a tumor may affect the activity of tumor-infiltrated CD4+ T cells.

Original languageEnglish
Pages (from-to)1461-1464
Number of pages4
JournalEuropean Journal of Immunology
Volume25
Issue number5
DOIs
Publication statusPublished - May 1995

Fingerprint

Semen
Glycoproteins
Breast Neoplasms
Microfilament Proteins
Proteins
Prolactin
Sepharose
Monoclonal Antibodies
T-Lymphocytes
Histocompatibility Antigens Class II
Protein Sequence Analysis
Helper-Inducer T-Lymphocytes
Affinity Chromatography
Recombinant Proteins
Neoplasms
Complementary DNA
HIV
Hormones
Bacteria
Biopsy

Keywords

  • Breast cancer
  • CD4
  • Seminal plasma

ASJC Scopus subject areas

  • Immunology

Cite this

Autiero, M., Cammarota, G., Friedlein, A., Zulauf, M., Chiappetta, G., Dragone, V., & Guardiola, J. (1995). A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. European Journal of Immunology, 25(5), 1461-1464. https://doi.org/10.1002/eji.1830250550

A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. / Autiero, Monica; Cammarota, Giancarlo; Friedlein, Arno; Zulauf, Martin; Chiappetta, Gennaro; Dragone, Vincenzo; Guardiola, John.

In: European Journal of Immunology, Vol. 25, No. 5, 05.1995, p. 1461-1464.

Research output: Contribution to journalArticle

Autiero, M, Cammarota, G, Friedlein, A, Zulauf, M, Chiappetta, G, Dragone, V & Guardiola, J 1995, 'A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells', European Journal of Immunology, vol. 25, no. 5, pp. 1461-1464. https://doi.org/10.1002/eji.1830250550
Autiero M, Cammarota G, Friedlein A, Zulauf M, Chiappetta G, Dragone V et al. A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. European Journal of Immunology. 1995 May;25(5):1461-1464. https://doi.org/10.1002/eji.1830250550
Autiero, Monica ; Cammarota, Giancarlo ; Friedlein, Arno ; Zulauf, Martin ; Chiappetta, Gennaro ; Dragone, Vincenzo ; Guardiola, John. / A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells. In: European Journal of Immunology. 1995 ; Vol. 25, No. 5. pp. 1461-1464.
@article{23286618658341dd8635df64b8e77a60,
title = "A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells",
abstract = "We previously isolated gp17, a human seminal plasma glycoprotein, which specifically interacts with the D1-D2 region of CD4, a T cell surface molecule involved in antigen recognition mediated by helper T cells also acting as a receptor for the human immunodeficiency virus. In this study we report that monoclonal antibodies (mAb) reacting with gp17 are able to inhibit the binding of gp17 to immobilized soluble CD4. An immunohistochemical analysis shows that gp17 is also expressed in mammary tumor cells upon hormone treatment and in biopsies from breast cancer patients. A structural characterization of gp17, including amino acid sequencing, indicates that the protein has an extensive structural similarity with a glycoprotein designated as seminal actin-binding protein (SABP), also secreted by male sexual glands. SABP is in turn identical to gross cystic disease fluid protein-15 (GCDFP-15) or prolactin-inducible protein (PIP), a factor known as a highly specific and sensitive marker of primary and metastatic apocrine breast cancer. To establish further the correspondence of gp17 and GCDFP-15/PIP/SABP, the latter was expressed in bacteria from a cloned cDNA and purified by affinity chromatography to either anti-gp17 mAb-Sepharose or CD4-Sepharose. The purified recombinant protein is shown to inhibit the binding of labeled, pure g17 to immobilized soluble CD4. The finding that breast cancer cells express a protein able to interact with the CD4 domains involved in the recognition of class II major histocompatibility antigens suggests a possible mechanism by which a tumor may affect the activity of tumor-infiltrated CD4+ T cells.",
keywords = "Breast cancer, CD4, Seminal plasma",
author = "Monica Autiero and Giancarlo Cammarota and Arno Friedlein and Martin Zulauf and Gennaro Chiappetta and Vincenzo Dragone and John Guardiola",
year = "1995",
month = "5",
doi = "10.1002/eji.1830250550",
language = "English",
volume = "25",
pages = "1461--1464",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "wiley",
number = "5",

}

TY - JOUR

T1 - A 17-kDa CD4-binding glycoprotein present in human seminal plasma and in breast tumor cells

AU - Autiero, Monica

AU - Cammarota, Giancarlo

AU - Friedlein, Arno

AU - Zulauf, Martin

AU - Chiappetta, Gennaro

AU - Dragone, Vincenzo

AU - Guardiola, John

PY - 1995/5

Y1 - 1995/5

N2 - We previously isolated gp17, a human seminal plasma glycoprotein, which specifically interacts with the D1-D2 region of CD4, a T cell surface molecule involved in antigen recognition mediated by helper T cells also acting as a receptor for the human immunodeficiency virus. In this study we report that monoclonal antibodies (mAb) reacting with gp17 are able to inhibit the binding of gp17 to immobilized soluble CD4. An immunohistochemical analysis shows that gp17 is also expressed in mammary tumor cells upon hormone treatment and in biopsies from breast cancer patients. A structural characterization of gp17, including amino acid sequencing, indicates that the protein has an extensive structural similarity with a glycoprotein designated as seminal actin-binding protein (SABP), also secreted by male sexual glands. SABP is in turn identical to gross cystic disease fluid protein-15 (GCDFP-15) or prolactin-inducible protein (PIP), a factor known as a highly specific and sensitive marker of primary and metastatic apocrine breast cancer. To establish further the correspondence of gp17 and GCDFP-15/PIP/SABP, the latter was expressed in bacteria from a cloned cDNA and purified by affinity chromatography to either anti-gp17 mAb-Sepharose or CD4-Sepharose. The purified recombinant protein is shown to inhibit the binding of labeled, pure g17 to immobilized soluble CD4. The finding that breast cancer cells express a protein able to interact with the CD4 domains involved in the recognition of class II major histocompatibility antigens suggests a possible mechanism by which a tumor may affect the activity of tumor-infiltrated CD4+ T cells.

AB - We previously isolated gp17, a human seminal plasma glycoprotein, which specifically interacts with the D1-D2 region of CD4, a T cell surface molecule involved in antigen recognition mediated by helper T cells also acting as a receptor for the human immunodeficiency virus. In this study we report that monoclonal antibodies (mAb) reacting with gp17 are able to inhibit the binding of gp17 to immobilized soluble CD4. An immunohistochemical analysis shows that gp17 is also expressed in mammary tumor cells upon hormone treatment and in biopsies from breast cancer patients. A structural characterization of gp17, including amino acid sequencing, indicates that the protein has an extensive structural similarity with a glycoprotein designated as seminal actin-binding protein (SABP), also secreted by male sexual glands. SABP is in turn identical to gross cystic disease fluid protein-15 (GCDFP-15) or prolactin-inducible protein (PIP), a factor known as a highly specific and sensitive marker of primary and metastatic apocrine breast cancer. To establish further the correspondence of gp17 and GCDFP-15/PIP/SABP, the latter was expressed in bacteria from a cloned cDNA and purified by affinity chromatography to either anti-gp17 mAb-Sepharose or CD4-Sepharose. The purified recombinant protein is shown to inhibit the binding of labeled, pure g17 to immobilized soluble CD4. The finding that breast cancer cells express a protein able to interact with the CD4 domains involved in the recognition of class II major histocompatibility antigens suggests a possible mechanism by which a tumor may affect the activity of tumor-infiltrated CD4+ T cells.

KW - Breast cancer

KW - CD4

KW - Seminal plasma

UR - http://www.scopus.com/inward/record.url?scp=0029039970&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029039970&partnerID=8YFLogxK

U2 - 10.1002/eji.1830250550

DO - 10.1002/eji.1830250550

M3 - Article

C2 - 7774651

AN - SCOPUS:0029039970

VL - 25

SP - 1461

EP - 1464

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 5

ER -